Acute Leukemia Clinical Trials in Chicago, Illinois

4 studies are recruiting for acute leukemia in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

   The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of …

   Stage

   Phase 1

   Ages

   2 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   102 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT04811560 on ClinicalTrials.gov

2. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

3. BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

   This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT04187105 on ClinicalTrials.gov

4. A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

   The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphob…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT06207123 on ClinicalTrials.gov